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The immunogenicity of a vaccine formulation is closely related to the effective internalization by the
innate immune cells that provide prolonged and simultaneous delivery of antigen and adjuvant to
relevant antigen presenting cells. Endosome associated TLR9 recognizes microbial unmethylated CpG
DNA. Clinical applications of TLR9 ligands are significantly hampered due to their pre-mature in vivo
digestion and rapid clearance. Liposome encapsulation is a powerful tool to increase in vivo stability as
well as enhancing internalization of its cargo to relevant immune cells. The present study established
that encapsulating CpG motifs in different liposomes having different physicochemical properties altered
not only encapsulation efficiency, but also the release and delivery rates that ultimately impacted in vitro
and ex-vivo cytokine production rates and types. Moreover, different liposomes encapsulating CpG ODN
significantly increased Th1-biased cytokines and chemokines gene transcripts Additional studies
demonstrated that co-stimulatory and surface marker molecules significantly upregulated upon lipo-
some/CpG injection. Finally, co-encapsulating model antigen ovalbumin with CpG ODN adjuvant in
nanoliposomes profoundly augmented Th1 and cell mediated anti-Ova specific immune response.
Collectively, this work established an unappreciated immunoregulatory property of nanoliposomes
mediating immunity against protein antigen and could be harnessed to design more effective therapeutic
vaccines or stand alone immunoprotective agents targeting infectious diseases, as well as cancer or
allergy.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Innate immune cells respond todiverse components ofmicrobial
pathogens. These molecular patterns collectively are known as the
pathogen associated molecular patterns (PAMPs). Host cell
expressed pattern recognition receptors (PRRs) [1] recognizes
PAMPs and generally initiates a signaling cascade leading to
orchestrated innate immune activation [2]. The most studied PRR
family is the Toll-like receptors (TLRs) [3,4], which are expressed by
various cells of tissues such as spleen, lung, muscle, intestines and
blood cells [5,6]. Recognition of diverse array of microbial compo-
nents bydifferent TLRs separates self antigen fromnon-self antigens
[7] and it is the link between innate and adaptive immunity [8,9].
Microbial nucleic acids are recognized by endosomal Toll-likeax: þ90 312 266 50 97.
sel).
ology, Max Planck Institute of
All rights reserved.receptors on immune system cells of the vertebrates. Bacterial DNA
containing CpG motifs and dsRNA, are recognized by TLR9 [10,11]
and TLR3 [12] respectively in both murine and human immune
cells whereas ssRNA are recognized by murine TLR7 and human
TLR8 [13]. Certain TLRs induce a Th1 dominant immune response,
yet others may drive a Th2-biased immune activation through
MyD88 or TRIF pathways [14]. CpG ODNs with different sequences
can also yield differential immune response [15,16]. CpG-B (or
K-ODN) triggers monocytes and B cells to proliferate and secrete
IL6 and IgM [15]. Moreover it induces plasmacytoid dendritic cells
(pDC) tomature and also secrete TNFa by proceeding signaling from
late endosome through MyD88 and IRF5. Whereas, CpG-A (or D-
ODNs) induces pDCs to secrete IFNa [17] by signaling from early
endosome through MyD88 and IRF7 [18] and it induces NK cells to
produce IFNg [15].
Nucleic acid based TLR ligands are promising vaccine adjuvants,
anti-allergens, immunoprotective and anticancer agents [19].
However their clinical applications are significantly hampered due
to their pre-mature in vivo digestion by endonucleases and rapid
clearance via serum protein adsorption leading to limited in vivo
Table 2
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encapsulating nucleic acid based TLR ligands into a depot carrier,
whereas provide an increased in vivo stability as well as more
pronounced targeting/internalization to relevant innate immune
cells [21e23]. Liposomal encapsulation is an efficient tool that can
improve stability, reduce pre-mature clearance and increase ther-
apeutic efficiency of its cargo by prolonging the duration in circu-
lation and thus improve bioavailability to relevant cells.
Liposomes are synthetically made phospholipids vesicle bila-
yers. By mixing various types of phospholipids with different
molar ratios, it is possible to generate different liposomes pos-
sessing different physicochemical characteristics ranging from
lamellarity to size or net surface charge [23] as well as PEG
mediated hydrated surface. In this study, two different classes of
TLR9 ligands (K and D-type CpG motifs) were encapsulated within
five different liposomes possessing different surface charge and
modification. The characteristic of liposome-ODN mediated differ-
ential innate immune activationwas evaluated. Moreover, potential
of these liposomes co-encapsulating antigen and adjuvant as
vaccine carriers were also assessed.
2. Materials and methods
2.1. Reagents
All cell culture media components were from Hyclone (USA). Cytokine ELISA
reagents such as recombinant cytokines, monoclonal unlabeled and biotinylated
antibodies against IL6 and IFNg, streptavidin-alkaline phosphatase (SAeAKP) and
p-nitrophenyl phosphate disodium salt substrate (PNPP) were purchased from
Thermo Scientific or Endogen Pierce (USA). Immunoglobulin ELISA reagents; goat
anti-mouse IgG, IgG1, IgG2a, IgG2b monoclonal antibodies conjugated with alkaline
phosphatase (AP) were from Southern Biotech (USA). Injectable endotoxin-free OVA
was obtained from Pierce (USA). DNase/RNase free water was obtained from
Hyclone (USA). TRI Reagent (Trizol) for RNA isolation was from Invitrogen (USA).
DyNAmo cDNA Synthesis kit, DyNAzyme II PCRMasterMix for PCRwas obtained
from Finnzymes (Finland). 10e150 bp DNA ladder was from Fermentas, and
100e1000 bp DNA ladder was from Jena Bioscience.
L-a-Phosphatidylcholine (PC) was purchased from Sigma Aldrich (USA).
Cholesterol (Chol), 3b-[N-(N0 ,N0-Dimethylaminoethane)-carbamoyl]Cholesterol
Hydrochloride (DC-Chol), 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-
[Methoxy(Polyethylene glycol)-2000] (Ammonium Salt) (PEG-PE), 1,2-Dioleoyl-
sn-Glycero-3-Phosphoethanolamine (DOPE) were all from Avanti Polar Lipids (USA).
Heidolph Laborota Collegiate Rotary Evaporator (Germany), Vibra Cell cup type
sonicator (Sonics and Materials Co., USA) and Maxi Dry Lyo, Heto-Holten (Denmark)
freeze dryer were used during liposome preparation.
2.2. TLR ligands
TLR ligands for stimulation assays were as follows and supplied from several
vendors: peptidoglycan (PGN) isolated from B.subtilis; (Fluka, Switzerland), lipo-
polysaccharide (LPS) (isolated from E.coli; Sigma, USA), and different classes of CpG
motif expressing ODN and control GpC ODNs (please see Table 1 for sequence and
size details) were synthesized by Alpha DNA (Montreal, Canada), and was kindly
provided by Dr. Dennis M. Klinman (NCI/NIH, USA). All ODNs were free of endotoxin
and protein. Bases shown in capital letter have phosphorothioate linkage and those
in lower case have phosphodiester linkages. CpG or flip (GpC) motifs are underlined.
2.3. Maintenance of animals
Adult male or female BALB/c or C57/BL6 mice (6e10 weeks old) were used for in
vivo experiments as well as generating primary spleen cells for in vitro assays. TheTable 1
Names, sizes and sequences of the CpG ODNs used in stimulation assays.
ODN Name and Size Sequence
1555 (15mer) K-type GCTAGACGTTAGCGT
K23 (12mer) K-type TCGAGCGTTCTC
D35 (20mer) D-type GGtgcatcgatgcaggggGG
D3CG (20mer) D-type GGtcgatcgatcgaggggGG
1612 (15mer) Control ODN K-type GCTAGAGCTTAGGCT
I-127 (20mer) Control ODN D-type GGtgcatgcatgcaggggGGanimals were kept in the animal holding facility of the Department of Molecular
Biology and Genetics at Bilkent University under controlled ambient conditions
(22  2 C) regulated with 12 h light and 12 h dark cycles. They were provided with
unlimited access of food and water. All experimental procedures have been
approved by the animal ethical committee of Bilkent University (Bil-AEC, Protocol
# 07/0029).
2.4. Liposome preparation
Cholesterol and various phospholipids (Avanti Polar Lipids, Alabaster, AL) were
combined in different ratios as shown in Table 2. Lipids were prepared in chloroform
as stock solutions of 10 mg/ml and were stored at 40 C until use. The liposome
preparation method was reported earlier [23].
Briefly, different ratios of phospholipid mixtures in chloroformwere evaporated
in a round bottom flask using a rotary evaporator at 37 C for 45e60min. The solvent
free lipid film was purged with argon or nitrogen to eliminate residual chloroform
and replace oxygen, thereby preventing lipid peroxidation. To generate empty
multilamellar vesicles (MLVs), sterile glass beads and 1 ml of PBS was added to each
20 mmol total dry lipid film. The MLV solution was then taken into sterile glass vial
and sonicated 5e8 times for 30 s intervals at 4 C using a cup sonicator. The
generated small unilamellar vesicles (SUVs) were then mixed with 1 mg/ml ODN
solution, and promptly frozen in liquid nitrogen and then freeze dried overnight. At
this stage, the lipid/ODN powder is formed.
ODN encapsulation within the liposomes was achieved during controlled-
rehydration step20. DNase/RNase free dH2O (1:10 ratio of original solution volume
before freezing) was added onto dehydrated ODN/liposome powder and vigorously
vortexed for 15 s every 5 min for 30 min at room temperature. At the end of 30 min,
PBS (1:10 original SUV/ODN solution volume) was added and gently mixed for
10 min. The liposome solution was completed to one ml by adding PBS and a final
liposome concentration of 20 mM lipid/mg DNA is adjusted. The size of the final
liposome preparation was reduced to <150 nm by extrusion through polycarbonate
filters. Liposome formulations were stored at 4 C until use.
2.5. Stimulation assays
BALB/c mice (3 months old) were sacrificed and their spleens were extracted.
Single-cell suspensions from spleens were prepared in RPMI 1640 supplemented
with 5% FCS, 50 mg/ml penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES,
0.11 mg/ml sodium pyruvate and 0.5 mM 2-ME. 4  105 cells were layered in each
well of 96 well microtiter plates. Cells were stimulated with defined concentrations
of ODNs and liposome formulations in triplicate. Final cell concentration at eachwell
was adjusted to 2  106 cells/ml. The cells were cultured at 37 C in a 5% CO2
incubator for 36 h unless otherwise stated. After incubation supernatant were
collected and stored at 20 C for further use.
2.6. ELISA
The 96-well microtiter plates (Nunc, Denmark) were coated with 10 mg/ml of
Abs that are specific for mouse IFNg and IL6. The plates were blocked with PBS-5%
BSA. Supernatants from cultured cells were added. Following the steps of incubating
with biotin-labeled anti-cytokine Ab and phosphate-conjugated avidin and PnPP
substrate, the cytokine content were quantitated according to standard curves
generated by using known amount of recombinant mouse cytokines.
2.7. Semi-quantitative RT-PCR
Total RNA from 1 107 of stimulated single-cell suspension of splenocytes were
extracted by Trizol extractionmethod. Synthesis of single-stranded DNA frommRNA
was performed by cDNA synthesis kit (Finnzymes cDNA synthesis kit, Finland)
according to themanufacturer’s protocol. PCRwas performed using 12.5 ml of master
mix (Finnzymes PCR Master Mix, Finland) 1 mg cDNA, 10 pmol/ml sense primer,
10 pmol/ml antisense primer and 9.5 ml of ddH2O. PCR conditions for b-actin, CD40
and IL18; 94 C for 30s, 55 C for 30s, 72 C for 30s, 34 cycles and final extension atLipid composition and molar ratios used to generate different liposome types.








PC, phosphatidylcholine; Chol, cholesterol; DOPE, dioleylphosphatidylethanol-
amine; PS, phosphatidylserine; DC-Chol, dimethylaminoethanecarbamol-choles-
terol; PEG-PE, polyethylene glycol phosphatididyl ethanolamine.
Table 3
Primer sets and expected amplification products used in the RT-PCR assay.
Gene Product Size Sense primer Antisense primer
mbactin 450-bp GTATGCCTCGGTCGTACCA CTTCTGCATCCTGTCAGCAA
mIFNa 92-bp TCAAGTGGCATAGATGTGGAAGAA TGGCTCTGCAGGATTTTCATG
mCD40 91-bp GTCATCTGTGGTTTAAAGTCCCG AGAGAAACACCCCGAAAATGG
mIL18 384-bp GATCAAAGTGCCAGTGAACC ACAAACCCTCCCCACCTAAC
E. Erikçi et al. / Biomaterials 32 (2011) 1715e1723 171772 C for 5 min, for IFNa; initial denaturation at 94 C for 2min, 94 C for 30s, 64.3 C
for 30s, 72 C for 1 min, 40 cycles and final extension at 72 C for 10 min. Primers
used in the RT-PCR assay is presented in Table 3.
2.8. Cell viability assay
1  104 to 2.5  104 spleen cells were stimulated by 0.1 mM of free CpG ODN,
liposomes alone and CpG ODN encapsulating liposomes in 96-well plates. After 48 h
of incubation the assay was performed according to the protocol of Cell Counting
Kit-8 (Dojindo-Japan).
2.9. Cell surface marker staining and analysis by FACS
For FACS analysis, original cell stock (2  106 cells) was transferred to 15 ml
falcon tube. Total volumewas completed to 1 ml with specific ODNs in 500 ml 5% FBS
supplemented oligo medium. Final oligo concentration was 1 mM, unless otherwise
stated. Incubation periods were 6e72 h for FACS analysis depending on the marker
to be examined. Falcon tubes were left in tilted position with loosened caps to allow
airflow during the incubation period in CO2 incubator.
Cells were centrifuged at 1500 rpm for 7min at the end of the incubation period.
Supernatant was sucked. The protocol was slightly modified from earlier studies
[15,17]. Briefly, pellet was disturbed by using a pin rack holder. If cells were to be
stained and analyzed later, cells were fixed in 50 ml fixationmedium (Caltag, Austria)
and transferred to 1.5 ml eppendorf tubes. Cells were incubated in dark at room
temperature for 15 min 1 ml PBS-BSA-Na azide was added into each tube to wash
cells. Cells were spun at 2000 rpm for 5 min. Supernatant was discarded and the
washing step was repeated. At the end of the second washing step, PBS-BSA-Na
azide was discarded and cells were incubated in fresh 50 ml PBS-BSA-Na azide
containing 3 ml of FITC-associated monoclonal antibody against CD86 (BD Phar-
mingen). If cells were to be stained and analyzed immediately, fixation was not
required. The cells can be stained in 50 ml PBS-BSA-Na azide containing 2e6 ml of
fluorochrome-associated cell surface marker. The remaining steps are similar but all
steps were performed on ice if cells were not fixed. Cells were washed twice,
resuspended in 500 ml PBS-BSA-Na azide, transferred to FACS tubes and analyzed in
FACS Calibur (BD, USA).
2.10. Immunization protocol with specific ODNs and OVA
Adult male C57/BL6 mice (5/group) were injected intraperitoneally (ip) with
15 mg of D35, D35 encapsulated anionic liposomes or control ODN and 7.5 mg of OVA.
Fourteen days later, booster injectionwas performed ip with the same ODN and OVA
formulations. Animals were tail bled one day before each injection. Blood was
incubated (to obtain mouse sera) at 37 C for 1.5 h, the clot was discarded and then
the remaining part was spun at 13200 rpm for 1 min. The serum was collected and
stored at 20 C for further use. Animals were sacrificed on day twenty-eight and
their spleens were removed. Half of the spleen was used to obtain single-cellTable 4






Percent ODN Release b (%)
1mo 3mo
Neutral 67.4  5.6 74.9  3.3 4.9  3.3 13.3  3.7
Anionic 71.5  4.2 89.5  4.6 9.5  4.6 21.5  7.9
Cationic 93.1  6.7 84.1  2.4 3.1  2.4 7.3  4.7
Stealth 78.9  2.0 76.7  3.8 6.9  3.8 14.9  3.6
SSCL 85.4  10.2 86.7  3.5 5.4  3.5 9.0  3.7
All ODN measurements were done using 1555 (K-Type) and D35 (D-Type) CpG
ODNs. Triplicate runs from at least three independent liposome preparations were
recorded. Data represents Ave  SEM.
a OD260 nm from supernatants were used to calculate loading efficiency
following liposome centrifugation.
b Liposome shelf-life stability following 1 or 3 months of storage @ 4 C was
measured after liposome pellet was separated by centrifugation. The ODN content
was calculated from supernatants by OD readings.splenocyte suspension and were incubated to compare IFNg secretion following in
vitro 7.5 mg of OVA stimulation.
2.11. Statististical analysis
Statistical analysis was performed in SigmaSTAT 3.5 software. Student’s t-test
was used to evaluate the statistical differences between untreated groups, (or
control-ODNs treated groups) with ODN-treated groups.3. Results
3.1. Stability and release properties of nanoliposomes
Initial optimization studies aimed to establish the ODN loading
efficiencies as well as in vitro release behavior and estimation of
shelf-life stability when the formulations are kept at 4 C following
reconstitution. As seen in Table 4, all liposome formulations gave
over 60% of ODN encapsulation upon reconstitution. Consistent
with previous findings [23], the highest ODN loadingwas with SSCL
liposome (Mean  SEM: 85.4  11.2%) and the lowest was with
Neutral liposome (67.4  5.6%, and Table 4). Interestingly a signifi-
cant difference between the loading efficiencies of K-ODN was
observed when cationic lipids were included in the liposome
preparation. For K-ODN the in vitro release (at 37 C with mild
shaking) into PBS was followed for eight days (Fig. 1). Anionic
liposome released 40% of its cargo whereas, SSCL type of liposome
released only 14% at the end of 8 d period (Fig. 1). The shelf-life
stability (at 4 C) was followed for three months. It was observed
that nearly all formulations had substantially good shelf-life. While
Anionic liposome retained nearly 80% of its cargo at 4 C, Cationic
liposome retained over 92% of of its cargo (Mean  SEM: 21.5  7.9
vs 7.3  4.7) (Table 4). Collectively, these results implicate that
current liposome formulations are an efficient depot system to
store and deliver ODNs. The developed entrapment method of ODN
within liposomes is mild and suitable for labile molecule encap-
sulations. To establish that liposome encapsulating ODNs retained






































Fig. 1. Time dependent cumulative ODN release from different liposome formulations.
Release of K-ODN @ 37 C into PBS (while mild shaking) was followed by OD readings
from supernatants after obtaining the liposome pellet.
E. Erikçi et al. / Biomaterials 32 (2011) 1715e172317183.2. In vitro activities of liposomal formulations
To compare the activity of K-ODN (1555, or K23) and D-ODN
(D35, and D35-3CG) alone or when they are encapsulated into five
different liposome types, spleen cells were stimulated with various
doses of free or liposome encapsulating CpG ODNs. IFNg and IL6
production were checked from cell supernatants by ELISA. While
free 1555 ODN is active at 0.3 mM concentration (it yielded
35.6  11.3 ng/ml, IL6 and 628  18 pg/ml, IFNg) when used with
cationic and SSCL liposomes, it induced significantly high IFNg than
the free form (approximately 35  5 and 25  4 fold moreFig. 2. IFNg and IL6 production by splenocytes following stimulation with CpG ODN 1555.
anionic, cationic, stealth or SSCL liposomes. Fold change of IFNg and IL6 levels in cell supern
index was based on 1555 mediated induction levels) for IFNg, 628  18 pg/ml, and for IL6, 3
and 3 mM of K23 (b) and D35 (c) either free (No Lipo) or within neutral, anionic, ca
(PGN) (5 mg/ml) and various liposomes without CpG ODNs were used as positive and negat
were detected by ELISA. Data are representative of five independent experiments run in trrespectively, Fig. 2a, p > 0.001). This augmented activity is solely
dependent on the encapsulated CpG ODN, since neither the free
liposome itself nor the liposomes encapsulating the control ODNs
were active (Fig. 2d). IL6 response is also high for 1555 encapsu-
lating SSCL liposome (3 fold more IL6 compared to free ODN,
p > 0.01). However, in neutral, stealth or anionic liposomes 1555
CpG ODN activity was lost (Fig. 2a).
Alternative design of K-ODN, K23, was also used for stimulation.
Of note themost distinguishable features of K23 from 1555 are, K23
is shorter (12mer vs 15mer) and it contains two CpG motifs in its
sequence, whereas 1555 is 15-mer and has only one CpG motif. ToSplenocytes was stimulated with 0.3 mM of 1555 either in solution or within neutral,
atants was calculated according to stimulation with No Lipo (i.e. only 1555; stimulation
5.6  11.3 ng/ml. IFNg and IL6), (a). Splenocytes were stimulated with 0.3 mM , 1 mM
tionic, stealth or SSCL liposomes. (d) Lipopolysacharide (LPS) (5 mg/ml), peptidoglycan
ive controls. Cell supernatants were collected at 36 h of incubation IFNg and IL6 levels
iplicates. * not determined, **; not detectable.
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tions, the cytokine production levels (IFNg and IL6) from spleen
cells, resembled more to D-Type ODN-liposome stimulations rather
than 1555-liposome formulation activities. At the lowest dose of
K23 (0.3 mM) neutral and anionic liposomes gave 3 fold more IL6
(Fig. 2b). Although free K23 could not stimulate any detectable IFNg
secretion at that concentration, K23 ODN in neutral or anionic
liposomes induced approximately 5 and 10 fold more IFNg secre-
tion (p > 0.01), respectively. Considering the lowest stimulation
dose, while 1555 induces the strongest IFNg and IL6 secretionwhen
they are encapsulated into SSCL liposome, K23 (Fig. 2b) and D35
(Fig. 2c) yielded robust cytokine production either with anionic or
neutral liposomes but not with SSCL. As the dose of ODNs
increased, the IFNg secretion increased correspondingly (Fig. 2b
and c). Stimulation with D-ODN encapsulating various liposomes
yielded cytokine responses unparallel to ODN1555 type. IFNg and
IL6 production from mouse splenocytes were significantly
increased when D-ODN was encapsulated in neutral, anionic or
stealth liposomes but not in cationic or SSCL liposomes (Fig. 2c).
These results strongly support the view of differential immune
activation by different liposomes. To determine whether loss of
IFNg is due to a shift in the cytokine milieu towards a Th2-biased
immune response, IL4 levels in cell supernatants were also
checked, (IL4 suppresses IFNg production [24]). IL4 was not
detected in any of liposome/ODN-treated cell supernatants (data
not shown).
3.3. Cytokine expression by liposomal formulations
We have speculated that positively charged liposomes could
alter subcellular location of D-ODN and thus prevent signaling to
initiate from early endosome through MyD88 and IRF7. If this is
the case, therefore, IFNa transcript levels should be lower upon
stimulation with cationic and SSCL liposomes compared to
neutral, anionic or stealth liposomes (liposome types lackingFig. 3. IFNa, CD40 and IL18 transcript levels of spleen cells upon K-ODN and D-ODN stimula
D-type ODN alone (No Lipo) or with various combinations of liposomes (neutral, anionic,
isolated and RT-PCR was performed.positively charged lipid). Total RNA of spleen cells were purified
1h or 8h after stimulations, and transcript levels of IFNa, in
addition to IL18 and CD40 was checked by RT-PCR. As shown in
Fig. 3, positively charged liposomes (Cationic and SSCL lipo-
somes) encapsulating D35 (or D-3CG ODN) gave either similar or
lower levels of mRNA transcripts for the tested cytokines and
surface marker molecule CD40 to that of free D35. The transcript
levels of spleen cells stimulated with neutral, anionic and stealth
liposomes encapsulating D35 surpassed the performance of free
or control D-ODN encapsulating liposomes (Fig. 3). As expected,
CpG ODN 1555 (or K23 ODN) did not induce production of IFNa
message. These results strongly suggested that when positively
charged liposomes are internalized by immune cells they
possibly either interfere or modify the fate of D-ODN subcellular
localization and alter IFNa secretion effect. Neutral or negatively
charged liposome formulations improved TLR9/D-ODN interaction
and induced more pronounced IFNa transcipt. Of note, no signifi-
cant differencewas detected either in CD40or in IL18 genemessage
levels following free or liposomal CpG ODN stimulations (i.e. 1 or
8 h).
3.4. Liposomal CpG ODN mediated proliferation
Cell viability and proliferation assays were performed to reveal
the cytotoxic or proliferative effect of stimulation with free CpG
ODN, and their liposome encapsulated forms on spleen cells. There
was no adverse effect on cell viability when the liposome encap-
sulating ODN ligands were used to treat the spleen cells (data not
shown). Table 5 summarizes proliferative index upon treatment
with different liposome formulations. As expected all ODN
sequences in their free forms induced very strong cell proliferation.
Neutral and stealth liposomes were neither significantly contrib-
uting nor inhibiting the proliferative potential of the ligands.
Cationic, anionic and SSCL liposome types, however, reduced the
degree of ligand dependent cell division.tion. 10  106 spleen cells were stimulated with 1 mM control ODN (1612), K-type and
cationic, stealth, SSCL). After 1 h and 8 h of incubation, total RNA of splenocytes was
Table 5
Cell proliferation following treatment either with free or liposome encapsulating
TLR ligands.
Types No Ligand Control ODN 1555 D-35
No Lipo 1.00  0.09 1.38  0.12 8.38  1.47** 5.77  0.65**
Neutral Lipo 1.55  0.42 2.35  0.92 5.55  1.39** 4.30  0.74*
Anionic Lipo 0.92  0.34 1.56  0.22 2.16  0.82 3.81  0.53*
Cationic Lipo 1.12  0.45 1.65  0.50 1.15  0.10 1.89  0.52
Stealth Lipo 1.34  0.23 2.08  0.54 3.88  1.14* 2.48  0.64*
SSCL Lipo 0.89  0.44 1.29  0.24 1.69  0.44 1.21  0.31
Stimulation index (SI) values are given. SI is calculated as the fold proliferation over
untreated cells. Triplicate wells (Ave  SEM) of two independent experiments are
reported, * 0.05 < p, ** 0.01 < p compared to untreated (no ligand) group.
E. Erikçi et al. / Biomaterials 32 (2011) 1715e172317203.5. APC activation by liposomal D-ODN
A naive T cell requires a second signal to proliferate and differ-
entiate into effector T cells following engagement with an antigen.
This second signal is known as co-stimulation. Co-stimulation is
mediated by co-stimulatory molecules, such as B7-1 (CD80) and
B7-2 (CD86) expressed on mouse antigen presenting cells (APCs)
including DCs, macrophages and B cells. The CD86 is expressed
constitutively at low levels on APCs and its upregulation is initiated
upon recognition either by a PAMP (i.e. through TLR triggering) or
exposure to inflammatory cytokines such as IFNg, IL12 or IL6. Of
note, the CD80 upregulation requires longer exposure andmay take
days [25,26]. We investigated the activation ability (by anti-CD86
staining) of APCs by liposomes encapsulating only D-Type ODN
ligand. This is due to the fact that, so far our findings indicated that
the most promising vaccine adjuvant candidate is D-ODN encap-
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Fig. 4. FACS analyses of CD86 positive DC populations following (a) in vitro stimulation and
encapsulating or free 1 mM D35 and the percentage of CD86 expressing cells were determ
encapsulated D35. 4 h later mice were sacrificed and their spleens were extracted. 2  106 s
determined by FACS.studies were only conducted with D-ODN formulations. Upon in
vitro stimulation with five different liposome formulations, CD86
staining by FACS revealed that previous IL6 and IFNg findings are in
accordance with the co-stimulatory molecule upregulation (Fig. 4A
and B). Similar to previous observations, the most potent formu-
lation was anionic liposome encapsulating D-ODN (12.7  1.2%
CD86 positive DC population). The least effective treatment was
again cationic and SSCL liposome types. Compared to free D-ODN,
more than 4 fold CD86 upregulation was obtained with anionic
liposomal D-ODN treatment.
The utmost aim of this study was to design an effective vaccine
carrier co-encapsulating adjuvant and antigen of interest in a single
depot package. As presented earlier, negatively charged liposomes
encapsulating D-ODN’s breadth of immune activity is more
pronounced than other studied ODNs. Although in vitro studies are
important, it does not warrant reproducible in vivo performance.
To reveal the in vivo activity of various liposome-D-ODN
formulations, mice were ip injected and 4h post-injection, spleen
cells were removed and ex-vivo cultured for an additional of 24h
(no further external stimulation at this stage) and then stainedwith
anti-CD86-FITC antibody to detect CD86 þ cells. Knowing that free
oligo is less stable than liposomal counterpart and also the inter-
nalization efficiencies of the free vs liposomal formulations vary at
great extend [23,27,28], we intentionally injected 2.5 fold more of
the free oligo (50 mg) during ip injections as opposed to 20 mg
liposomal D-ODN. As presented in Fig. 4, compared to untreated
animals, all tested free or liposomal D-ODN formulations induced
significantly higher CD86 upregulation fromDC. Among D35 group,
similar what was seen during in vitro assays, anionic-D35 gave the
most profound upregulation, (>3 fold more induction compared to
free D-ODN group) CD86 upregulation was also stronger eitherionic Cationic Stealth SSCL 
ionic Cationic Stealth SSCL
(b) in vivo stimulation. (A) 1  107 splenocytes were stimulated with various liposome
ined by FACS. (B) Mice were immunized with 50 mg of free D35 or various liposome
plenocytes were incubated for 24 h and then percentage of CD86 expressing cells were
E. Erikçi et al. / Biomaterials 32 (2011) 1715e1723 1721with neutral or stealth D-ODN encapsulating liposomes (19.1  1.5
and 18.5  2.0 respectively).
3.6. In vivo immunization studies
Following in-vitro and ex-vivo analyses, we next tested these
D-ODN-liposome formulations in immunization studies. For this,
a model protein antigen (Ovalbumin) was either mixed with free
D-ODN or co-encapsulated form in anionic liposomes were
prepared. Initial experiments revealed that encapsulating CpG and
mixing with free Ag, or encapsulating Ova in liposomes and mixing
with free D-ODN prior to injections had no significant contribution
to anti-Ova specific Ab titers (data not shown). Furthermore, two
different populations of liposomes (i.e. liposomal D-ODN and Ova
loaded liposomes) and mixing just before immunization also did
not significantly contribute anti-Ova Ab titers (data not shown).
As presented in Table 6, naive mice were divided into 5 different
treatment groups. Before primary injection background un-
immunized mouse sera was obtained. The next day (at d ¼ 0) mice
were i.p immunized with the indicated groups. On d ¼ 13, all
animals were tail bled and sera was saved to study primary anti-
OVA Ig responses by ELISA. The next day, booster injections were
performed. On d ¼ 28 mice were first bled and then sacrificed, and
spleens were frozen down for PCR study. The collected mouse
primary and secondary sera were subjected to total IgG, anti-OVA
IgG1, IgG2a and IgG2b ELISA following serial titrations (Table 6). It is
clearly demonstrated that present vaccine formulation (Gr#5), that
is, ovalbumin and D-ODN as the adjuvant, co-encapsulated in
a single liposome vesicle (anionic liposomes) induced >150 fold
more IgG over free Ag þ CpG mixed group (i.e. Gr# 3), and 14 fold
more fromAgþ Control ODN (Gr#4). In vaccine trials, in addition to
total IgG which is an indication of the generated humoral immu-
nity, it is very important to mount cell mediated immune response,
in which one can predict by analyzing the level of IgG2a titers. As
seen in (Table 6a), over 30 fold more IgG2a from anionic liposomes
co-encapsulating Ova and D-ODN (i.e. Gr#5) was detected
compared to Gr#3 (428  50 vs 14  7, respectively).
Booster injection is the cardinal phase of any vaccination
protocol, since it induces both effector T andmemory B cells against
injected antigen. As seen in Table 6b, a very potent anti-Ova
humoral immunity is initiated at the end of 4 weeks (Gr#5, Table
6b). A very strong improvement in total IgG (that corresponded
to>22 fold more IgG) was achieved when liposomal formulation is
used instead of its free formulation (Gr#5 and Gr#3 titers are 28670Table 6
Primary and secondary anti-Ova IgG subclass responses of mice immunized with free or
A. Primary IgG Levels
Gr.# Treatment Groups IgG
1 Untreated 7  4
2 Control ODN + OVA 7  4
3 D35 + OVA 28  14
4 Anionic Lipo(Control ODN + OVA) 300  150
5 Anionic Lipo(D35 + OVA) 4250  1000*
B. Secondary IgG Levels.
Gr.# Treatment Groups IgG
1 Untreated 7  1
2 Control ODN + OVA 7  2
3 D35 + OVA 1300  450
4 Anionic Lipo(Control ODN + OVA) 5168  2590*
5 Anionic Lipo(D35 + OVA) 28672  5050a**
Female Balb/c mice (6e8 wks old, 5/group) was immunized with OVA (5 mg/ml) plus cont
on d¼ 13 before booster injection. Twoweeks post-booster injectionmice were first tail b
reported as 1/T for primary and secondary antibody response. Results (mean titer SD) ar
significance of Gr#3 vs Gr#4 or Gr#5 paired t-test analysis comparison), ** 0.0001 < p (
a 0.001 < p (Gr#4 vs Gr#5 paired t-test analysis comparison).are 1300, respectively). Moreover, IgG1 anti-OVA titers were also
significantly higher with liposomal formulation (more than 26 fold
rose Gr#5 vs Gr#3). Of note, IgG2a level with Gr#5 was >13 fold
more compared to Gr#3 animals. To further investigate the ability
of the liposome formulation to mount cell mediated immune
response, IFNg production of the immunized animals were
analyzed from the recovered spleen cell supernatants following in
vitro Ova stimulation in culture for 36 h (Fig. 5). Data revealed that
over 7 fold more IFNg secretionwas detected from Gr#5 animals to
that of Gr#3 immunized mice. These findings collectively demon-
strated that delivery of D-ODN and Ova antigen encapsulated in
anionic liposome induced very strong humoral and cell mediated
immunity than free D-ODN plus Ova formulation (Table 6 and
Fig. 5).
4. Discussion
This work investigated the immune activity of liposomes
harboring different classes of CpG ODNs, an important immune
adjuvant intended for clinical use. In the present study, the shelf life
of the generated liposomes showed quite promising stability and
retention profiles up to three months (Table 4), duration much
longer than any conventional vaccination scheme. Moreover, we
demonstrated that K- and D-type ODNmediated cytokine secretion
is differentially controlled by the liposome surface charge (Fig. 2).
This data is in agreement with previously reported finding [23].
Interestingly, alternative design of K-ODN, K23, behaved differently
in liposomes optimal for 1555 sequence (Fig. 2b). The vesicle
lamellarity or the vesicle fluidity of the liposome formulations does
not seem to influence the resultant immune activation induced by
CpG ODNs, since the generated vesicles are kept at fixedmolar ratio
for all preparations and following liposome reconstitution their
sizes were reduced to less than 150 nm via extrusion.
We have revealed that neutral, stealth and anionic liposomes
encapsulating D-type ODNs boost IFNg secretion compared to free
form (Fig. 2c). Therefore we can conclude that neutral or anionic
liposomes encapsulating D-ODN can promote substantial amount
of cytokine secretion even at very low doses. Depot effect and
prevention of pre-mature clearance in addition to sparing ODN
from nuclease attack are important features provided by liposome
encapsulation.
We have suspected that positively charged liposomes prevent
ODN to be sequestered in early endosome where initiation of
D-ODN mediated signaling cascade is required [15e18] and isliposome encapsulating Ag and CpG ODN.
IgG1 IgG2a IgG2b
7  4 7  4 7  4
7  4 7  2 7  1
14  7 14  7 7  2
35  10 7  2 7  1
112  12* 428  50 7  1
IgG1 IgG2a IgG2b
7  2 7  2 7  4
7  4 7  2 7  1
828  245 112  12 112  12
4355  1430* 448  20* 112  20
21672  7150a** 1500  250a* 28  4
rol or CpG ODN (15 mg/ml) (free or liposome encapsulated forms) at day 1 and bleed
led and then sacrificed. Sera was titrated and assayed for anti-OVA IgG subclasses and
e combination of two independent experiments, *0.01< p (represent the statistiacal

































































Fig. 5. Female Balb/c mice (6e8 wks old, 5/group) was immunized with OVA (5 mg/ml) plus control or CpG ODN (15 mg/ml) (free or liposome encapsulated forms), two weeks post-
booster injection mice were sacrificed, spleen cells (5  106/ml) from each animal were recovered and cultured in the presence of 7.5 mg OVA for 36h. Supernatants were collected
and IFNg ELISA was studied to detect recall antigen response. Results are reported as IFNg (pg/ml) (mean  SD) for each group. Paired t-test analysis comparison between Gr#3 and
Gr#5 is P > 0.001.
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D35 encapsulating cationic and SSCL liposomes failed to induce
IFNa message as much as free D35 (following 8 h of treatment).
However, neutral, anionic and stealth liposomes induced signifi-
cantly high IFNa transcript (Fig. 3). Therefore, this data implied that
positively charged liposomes somehow interfere with D-ODN/TLR9
interaction in the early endosome.
CD40 is a receptor expressed on macrophages and important in
activation of infected macrophages with intracellular pathogens by
CD4 T cells expressing CD40 ligand. We demonstrated that free D35
also induces CD40 expression (Fig. 3). Therefore we can say that K-
ODN and D-ODN encapsulation into any of the liposomes do not
augment its expression compared to free form, however, positively
charged liposomes decreased the amount of CD40 transcript. IL18 is
considered as IFNg-inducing factor. Together with IL12, IL18
induces high amount of IFNg expression [29]. It is an important
cytokine in innate [30,31] and adaptive [32] immune regulation.
Except the free form, liposomal forms of D35 do not induce IL18
expression. We can conclude that IFNg induction by either lipo-
somal D-ODN or K-ODN is not maintained by increased levels of
IL18 production.
We observed that upon control ODN encapsulating liposome
treatment considerable levels of IFNa, CD40 and IL18 was induced
by immune cells. These stimulations are TLR independent since the
control ODN does not contain any active CpGmotif. However, it is of
great importance to evaluate the activity of control ODN that is
internalized into phagocytic cells within liposomes and whether it
initiates a signaling pathways through recognition by cytosolic DNA
sensors such as DAI [33] or AIM2 [34] and leads to these transcript
upregulations.
In vaccine induced immunity an important step is to strongly
activate T cells and for this co-stimulatory molecule upregulation
on APCs is critical [35e37]. In this study, unexpectedly, anionic
liposome encapsulating D-ODN consistently upregulated CD86
both upon in vitro and in vivo stimulation (Fig. 4). This effect was
very encouraging since raising cell mediated immunity is as
important as mounting a humoral response for the success of any
immunization.
Immunization with liposome encapsulating antigen and CpG
ODN compared to their free forms gave significantly high amount of
IgG titers in mice. This heightened anti-ova response is provided by
simultaneous signals delivered by the formulation leading toefficient naive T cell activation. In a depot vesicle formulation both
the antigen and CpG adjuvant are together and liposomes indeed
mimics a natural course of a pathogenic insult.
In the literature, Joseph et al. demonstrated that when mice
were vaccinated once with liposomes (DMPC:DMPG mole ratio of
9:1) co-encapsulating 25 mg CpG ODN and and 0.5 mg influenza
virus subunit hemagglutinin and neuraminidase (HN) antigen, no
detectable IgG1 titer and 550 IgG2a titer was observed at 21 days
post-injection [38]. We have injected mice with anionic liposome
co-encapsulating 7.5 mg ova and 15 mg D-ODN. Only 13 days later we
have obtained 122 IgG1 titer and 428 IgG2a titer. At the end of
4 weeks these titers were much higher than reported amounts by
Joseph et al. Although amount and type of CpG ODN as well as
antigen types and amounts are different, one can speculate that the
immune response initiated by D-ODN encapsulating anionic lipo-
some formulation is more immunogenic yielding stronger Th1-
biased immunity against tested ovalbumin.
We previously demonstrated that when mice immunized with
SSCL co-encapsulating 10 mg 1555 and 2 mg OVA. Following booster
injection, total IgG titer reached 19000, the present study showed
that a 1.5 fold more IgG (a titer of 28672) with a different type of
CpG ODN and liposome type could be attained. Collectively, the
present in vivo experiments demonstrated that contrary to the
established dogma that D-type ODN is not that immunogenic than
K-type, our findings suggests that when encapsulated within
a proper liposome, D-ODN can induce antigen specific immunity.
5. Conclusion
This study established that different liposomes induced differ-
ential innate immune activation otherwise not possible to obtain
with two different classes of TLR9 ligands (i.e. K- and D-types). The
information from this work demonstrated an unappreciated
feature of liposome-mediated immune modulation and could be
harnessed to design more effective therapeutic vaccines targeting
several infectious diseases, cancer and asthma or allergy.
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Appendix
Figures with essential color discrimination. Fig. 1 in this article
are difficult to interpret in black and white. The full color images
can be found in the on-line version, at doi:10.1016/j.biomaterials.
2010.10.054.
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